Related Experiment Videos
Effects of bisphosphonate on experimental jaw metastasis model in nude mice
A Sasaki1, A Nishiyama, R E Alcalde
1Department of Oral and Maxillofacial Surgery II, Okayama University Dental School, Japan. aksasaki@dent.okayama-u.ac.jp
Abstract:
The mechanism of osteolysis associated with metastatic cancer of the jaws is essentially osteoclast-mediated. Therefore, it is likely that potent osteoclastic bone resorption inhibitors such as bisphosphonates would be efficacious for the treatment of jaw metastasis. We examined the effects of a third generation bisphosphonate, YM175, in a nude mice jaw metastasis model with intracardiac injection of a human breast cancer cell line, MDA-MB-231. The metastatic lesions in untreated mice were radiographically observed at the body and angle of the mandible. Histology of the mandible of untreated mice revealed that most of the bone marrow cavities had been occupied by the metastatic tumor with active osteoclasts along the trabecular bone. The experimental group showed that YM175 markedly reduced the size of tumor and the number of osteoclasts. These results suggest that YM175 may suppress metastasis formation and tumor growth in jaw through inhibition of osteoclastic bone resorption.
Insights
This study shows that YM175, a bisphosphonate drug, effectively reduces jaw metastasis and osteoclast activity in mice. This suggests YM175 could be a promising treatment for bone cancer in the jaw.
Area of Science:
- Oncology
- Pharmacology
- Orthopedics
Background:
- Osteolysis in jaw metastases is primarily driven by osteoclasts.
- Bisphosphonates are potent inhibitors of osteoclastic bone resorption.
- This suggests bisphosphonates could treat jaw metastases.
Purpose of the Study:
- To investigate the efficacy of YM175, a third-generation bisphosphonate, in a mouse model of human breast cancer jaw metastasis.
- To evaluate YM175's impact on tumor growth and osteoclast activity within the jawbone.
Main Methods:
- A nude mouse model was established by intracardiac injection of human breast cancer cells (MDA-MB-231).
- YM175 was administered to the experimental group, while a control group received no treatment.
- Radiographic and histological analyses were performed on the mandibles of both groups.
Main Results:
- Untreated mice exhibited significant metastatic lesions in the mandible with abundant active osteoclasts.
- YM175 treatment markedly reduced the size of metastatic tumors in the jaw.
- The number of osteoclasts was significantly decreased in mice treated with YM175.
Conclusions:
- YM175 demonstrates significant potential in suppressing the formation and growth of jaw metastases.
- The drug's efficacy appears to be mediated through the inhibition of osteoclastic bone resorption.
- YM175 may represent a novel therapeutic strategy for managing metastatic cancer in the jaw.